['ANTACIDS: ANTACIDS (E.G., ALUMINIUM, MAGNESIUM HYDROXIDE, OR CALCIUM CARBONATE)', '\xe2\x86\x94 RILPIVIRINE (ANTACIDS TAKEN AT LEAST 2 HOURS BEFORE OR AT LEAST 4 HOURS AFTER RILPIVIRINE) \xe2\x86\x93 RILPIVIRINE (CONCOMITANT INTAKE)', 'THE COMBINATION OF COMPLERA AND ANTACIDS SHOULD BE USED WITH CAUTION AS COADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN RILPIVIRINE PLASMA CONCENTRATIONS (INCREASE IN GASTRIC PH). ANTACIDS SHOULD ONLY BE ADMINISTERED EITHER AT LEAST 2 HOURS BEFORE OR AT LEAST 4 HOURS AFTER COMPLERA.', 'AZOLE ANTIFUNGAL AGENTS: FLUCONAZOLE ITRACONAZOLE KETOCONAZOLE POSACONAZOLE VORICONAZOLE', '\xe2\x86\x91 RILPIVIRINE THE INTERACTION WAS EVALUATED IN A CLINICAL STUDY. ALL OTHER DRUG-DRUG INTERACTIONS SHOWN ARE PREDICTED. , THIS INTERACTION STUDY HAS BEEN PERFORMED WITH A DOSE HIGHER THAN THE RECOMMENDED DOSE FOR RILPIVIRINE. THE DOSING RECOMMENDATION IS APPLICABLE TO THE RECOMMENDED DOSE OF RILPIVIRINE 25 MG ONCE DAILY. \xe2\x86\x93 KETOCONAZOLE ,', 'CONCOMITANT USE OF COMPLERA WITH AZOLE ANTIFUNGAL AGENTS MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). NO DOSE ADJUSTMENT IS REQUIRED WHEN COMPLERA IS COADMINISTERED WITH AZOLE ANTIFUNGAL AGENTS. CLINICALLY MONITOR FOR BREAKTHROUGH FUNGAL INFECTIONS WHEN AZOLE ANTIFUNGALS ARE COADMINISTERED WITH COMPLERA.', 'H 2 -RECEPTOR ANTAGONISTS: CIMETIDINE FAMOTIDINE NIZATIDINE RANITIDINE', '\xe2\x86\x94 RILPIVIRINE , (FAMOTIDINE TAKEN 12 HOURS BEFORE RILPIVIRINE OR 4 HOURS AFTER RILPIVIRINE) \xe2\x86\x93 RILPIVIRINE , (FAMOTIDINE TAKEN 2 HOURS BEFORE RILPIVIRINE)', 'THE COMBINATION OF COMPLERA AND H 2 -RECEPTOR ANTAGONISTS SHOULD BE USED WITH CAUTION AS COADMINISTRATION MAY CAUSE SIGNIFICANT DECREASES IN RILPIVIRINE PLASMA CONCENTRATIONS (INCREASE IN GASTRIC PH). H 2 -RECEPTOR ANTAGONISTS SHOULD ONLY BE ADMINISTERED AT LEAST 12 HOURS BEFORE OR AT LEAST 4 HOURS AFTER COMPLERA.', 'MACROLIDE OR KETOLIDE ANTIBIOTICS: CLARITHROMYCIN ERYTHROMYCIN TELITHROMYCIN', '\xe2\x86\x91 RILPIVIRINE \xe2\x86\x94 CLARITHROMYCIN \xe2\x86\x94 ERYTHROMYCIN \xe2\x86\x94 TELITHROMYCIN', 'CONCOMITANT USE OF COMPLERA WITH CLARITHROMYCIN, ERYTHROMYCIN OR TELITHROMYCIN MAY CAUSE AN INCREASE IN THE PLASMA CONCENTRATIONS OF RILPIVIRINE (INHIBITION OF CYP3A ENZYMES). WHERE POSSIBLE, ALTERNATIVES SUCH AS AZITHROMYCIN SHOULD BE CONSIDERED.', 'NARCOTIC ANALGESICS : METHADONE', '\xe2\x86\x93 R(\xe2\x80\x93) METHADONE \xe2\x86\x93 S(+) METHADONE \xe2\x86\x94 RILPIVIRINE \xe2\x86\x94 METHADONE (WHEN USED WITH TENOFOVIR)', 'NO DOSE ADJUSTMENTS ARE REQUIRED WHEN INITIATING COADMINISTRATION OF METHADONE WITH COMPLERA. HOWEVER, CLINICAL MONITORING IS RECOMMENDED AS METHADONE MAINTENANCE THERAPY MAY NEED TO BE ADJUSTED IN SOME PATIENTS.']